IL17A and neoplasm: This may be achieved by inhibition of CXCR2 or IL-17 to reduce neutrophil migration into the tumor, or by anti-TGF-β that leads to a shift from N2 to the N1 phenotype of neutrophils with subsequent acquisition of antitumor activity [299,300,301] (Figure 2).